Zolbetuximab plus mFOLFOX6 and nivolumab led to meaningful gains in patients with unresectable gastric/gastroesophageal junction adenocarcinoma. The frontline combination of zolbetuximab (Vyloy), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback